Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panaxytriol is an unsaturated fatty alcohol classified as a polyacetylene compound and found naturally in the roots of Panax ginseng—specifically Korean red ginseng[2][3][4][11]. It is a bioactive constituent that has demonstrated significant anti-tumor and anti-inflammatory properties, including inhibition of several human cancer cell lines such as gastric carcinoma, lymphoma, breast carcinoma, and melanoma, in both in vitro and in vivo studies[3][7][9]. Mechanistically, panaxytriol acts in part by inducing phase 2 detoxification enzymes, such as quinone reductase, which contribute to cytoprotection against toxic insults and chemoprevention by promoting cellular defense responses to electrophiles and oxidative stress[1][3][5][7]. Additional activities include modulation of cytochrome P450 3A enzymes (CYP3A), affecting drug metabolism and possibly chemotherapeutic tolerance[2][5]. Panaxytriol has moderate neurotrophic activity and minimal toxicity at cytoprotective doses; analogs of the compound have exhibited increased potency without increased toxicity[3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on panaxytriol.